Weisen begins exports to the Middle East… supply contract with the largest medical company [이데일리 나은경 기자] Waysen, an artificial intelligence (AI) medtech company, announced on the 14th that it signed a strategic sales agreement for its medical AI solutions and healthcare products with Megamind, the largest medical company in the Middle East, located in … Read more
‘Chairman Chey Tae-won’s eldest daughter’ Choi Yoon-jung promoted to head of SK Biopharm’s business development division [이데일리 김새미 기자]Choi Yun-jeong, the eldest daughter of SK Group Chairman Tae-won Choi and team leader of SK Biopharm (326030), was promoted to head of SK Biopharm Business Development Division. Accordingly, the new division head Choi became the youngest … Read more
Bukwang Pharmaceutical receives product approval for ‘Latuda Tablet’, a new drug for the treatment of schizophrenia and type 1 bipolar depression [이데일리 나은경 기자] On the 23rd, Bukwang Pharmaceutical (003000) received approval from the Ministry of Food and Drug Safety for its new drug ‘Latuda Tablet’ (ingredient name: lurasidone hydrochloride) for the treatment of major … Read more
GI Innovation decides to register US patent for combination therapy including GI-101 and GI-102 (Provided by GI Innovation) [이데일리 김진호 기자]GI Innovation (358570) announced on the 15th that an additional U.S. patent has been registered for anti-cancer combination therapy including ‘GI-101’ or ‘GI-102’ discovered by the company. According to GI Innovation, this anticancer drug combination … Read more
[이데일리 김새미 기자] HLB (028300) announced on the 17th that its U.S. subsidiary Eleva has acquired the global rights (excluding Korea and China) for ‘Camrelizumab’, an immunotherapy drug being developed by China’s Hengshe Pharmaceutical as a liver cancer treatment. From the left, Eleva CEO Jeong Se-ho and Jin Yang-gon Chairman of HLB Group, Shun Piaoyang, … Read more
[이데일리 김진수 기자] Ildong Pharmaceutical announced on the 6th that it has received approval from the Ministry of Food and Drug Safety for phase 1 clinical trial of ‘ID110521156’, a new drug candidate in the field of metabolic diseases with a mechanism of GLP-1 receptor agonist. Ildong Pharmaceutical Headquarters. (Photo = Ildong Pharmaceutical) Ildong Pharmaceutical … Read more
Samsung Bioepis reviewing acquisition of Biogen’s biosimilar division [이데일리 김진수 기자] Samsung Bioepis is preparing to acquire the biosimilar division of US pharmaceutical company Biogen. If the acquisition is successful, it is expected to secure global sales competitiveness following the development and production of biosimilars. Samsung Bioepis office building. (Photo = Samsung Bioepis) According to … Read more
Yuhan Corporation publishes sustainability management report… Details of new drug development and R&D activities Yuhan Corporation Sustainability Report 2022-2023 Cover (Data = Yuhan Corporation) [이데일리 나은경 기자] Yuhan Corporation (000100) published a sustainability report on the 28th to transparently disclose its environmental, social, and governance (ESG) management performance and future plans for the past year … Read more